FATE · Fate Therapeutics Inc · Executive Compensation

$2.32 +0.02 (+0.87%) At close · Oct 2

Market Cap

$281.58M

119.82M

Volume · Oct 2 658.02K Avg daily vol (3M) 1.92M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Bahram Valamehr	Ph.D., MBA President, Chief Executive Officer and Director	$600,000	—	—	$1,283,868	$360,000	$4,700	$2,248,568
Cindy R. Tahl	Chief Legal & Compliance Officer and Corporate Secretary	$520,000	—	$92,400	$286,896	$208,000	$4,700	$1,111,996
Kamal Adawi	M.S., MBA Chief Financial Officer and Treasurer	$99,000	—	$115,500	$456,000	$39,600	$4,700	$714,800

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Scott Wolchko	CEO	$675,000	$405,000	$34,261	$3,056,208	—	$4,600	$4,175,069
J. Scott Wolchko	President, Chief Executive Officer, Chief Financial Officer and Director	$675,000	$405,000	$34,261	$3,056,208	—	$4,600	$4,175,069
Bahram Valamehr	Chief Research and Development Officer	$525,000	$147,000	$541,000	$2,367,000	—	$4,600	$3,584,600
Cindy R. Tahl	Chief Legal & Compliance Officer and Corporate Secretary	$500,000	$140,000	$541,000	$2,235,500	—	$4,600	$3,421,100

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Scott Wolchko	CEO	$645,000	—	—	$2,602,350	$270,900	$4,500	$3,522,750
J. Scott Wolchko	President, Chief Executive Officer, Chief Financial Officer and Director	$645,000	—	—	$2,602,350	$270,900	$4,500	$3,522,750
Bahram Valamehr	Chief Research and Development Officer	$500,000	—	—	$2,342,115	$140,000	$4,500	$2,986,615
Edward J. Dulac III	Chief Financial Officer	$475,000	—	—	$2,211,998	$133,000	$4,500	$2,824,498
Cindy R. Tahl	Chief Legal & Compliance Officer and Corporate Secretary	$475,000	—	—	$2,211,998	$133,000	$4,500	$2,824,498

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Scott Wolchko	CEO	$645,000	—	—	$7,500,000	—	—	$8,145,000
J. Scott Wolchko	President, Chief Executive Officer and Director	$645,000	—	—	$7,500,000	—	—	$8,145,000
Mark Plavsic	Chief Technology Officer	$455,000	—	$1,327,751	$1,375,000	$109,200	—	$3,266,951
Edward J. Dulac III	Chief Financial Officer	$455,000	—	$1,327,751	$1,375,000	—	—	$3,157,751
Bahram Valamehr	Chief Research and Development Officer	$455,000	—	$1,327,751	$1,375,000	—	—	$3,157,751
Cindy R. Tahl	General Counsel and Corporate Secretary	$455,000	—	$1,327,751	$1,375,000	—	—	$3,157,751
Yu-Waye Chu	Chief Medical Officer	$455,000	—	$1,327,751	$1,375,000	—	—	$3,157,751

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Scott Wolchko	CEO	$610,000	—	$9,552,617	$1,200,000	$366,000	—	$11,728,617
J. Scott Wolchko	President, Chief Executive Officer and Director	$610,000	—	$9,552,617	$1,200,000	$366,000	—	$11,728,617
Mark Plavsic	Chief Technology Officer	$230,137	—	$6,915,474	$993,361	$92,055	$148,000	$8,379,027
Bahram Valamehr	Chief Research and Development Officer	$430,000	—	$5,375,416	$500,000	$172,000	—	$6,477,416
Yu-Waye Chu	Chief Medical Officer	$430,000	—	$5,375,416	$500,000	$172,000	—	$6,477,416
Cindy R. Tahl	General Counsel and Corporate Secretary	$430,000	—	$5,375,416	$500,000	$172,000	—	$6,477,416
Edward J. Dulac III	Chief Financial Officer	$420,000	—	$5,296,051	$500,000	$168,000	—	$6,384,051

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Edward J. Dulac III	Chief Financial Officer	$142,500	$137,917	$1,420,800	$3,786,529	$75,833	$120,000	$5,683,579
J. Scott Wolchko	President, Chief Executive Officer and Director	$570,000	—	$1,451,340	$3,222,577	$356,250	—	$5,600,167
Scott Wolchko	CEO	$570,000	—	$1,451,340	$3,222,577	$356,250	—	$5,600,167
Cindy R. Tahl	General Counsel and Corporate Secretary	$390,000	—	$549,750	$1,324,347	$195,000	—	$2,459,097

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
J. Scott Wolchko	President, Chief Executive Officer and Director	$540,000	—	$4,137,500	$5,732,955	$310,500	—	$10,720,955
Scott Wolchko	CEO	$540,000	—	$4,137,500	$5,732,955	$310,500	—	$10,720,955
Cindy R. Tahl	General Counsel and Corporate Secretary	$375,000	—	$744,750	$1,547,898	$150,938	—	$2,818,586
Bahram Valamehr	Chief Development Officer	$375,000	—	$744,750	$1,547,898	$150,938	—	$2,818,586
Daniel D. Shoemaker	Chief Scientific Officer	$375,000	—	$744,750	$1,547,898	$150,938	—	$2,818,586

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Scott Wolchko	CEO	$516,000	—	—	$2,756,998	$258,000	—	$3,530,998
J. Scott Wolchko	President, Chief Executive Officer and Director	$516,000	—	—	$2,756,998	$258,000	—	$3,530,998
Bahram Valamehr	Chief Development Officer	$321,865	—	—	$2,138,235	$117,250	—	$2,577,350
Cindy R. Tahl	General Counsel and Corporate Secretary	$350,000	—	—	$906,465	$122,500	—	$1,378,965

Fiscal 2017

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
J. Scott Wolchko	President, Chief Executive Officer and Director	$480,000	—	—	$668,789	$156,000	—	$1,304,789
Scott Wolchko	CEO	$480,000	—	—	$668,789	$156,000	—	$1,304,789

Executive changes

Person	Role	Change	Effective	Filed
Laura J. Hamill	Class I Director	Appointed	2026-06-12	2026-06-15
Karin Jooss, Ph.D.	Class I Director	Appointed	2026-06-12	2026-06-15
Robert S. Epstein, M.D., M.S.	Class I Director	Appointed	2026-06-12	2026-06-15
Kamal Adawi	Chief Financial Officer	Appointed	2025-10-20	2025-10-14
Neelufar Mozaffarian	Board	Resigned	2025-10-13	2025-10-14
John D. Mendlein	Board	Resigned	2025-10-13	2025-10-14
Timothy P. Coughlin	member of the Board and the Audit Committee	Terminated	2025-05-29	2025-05-30
Matthew Abernethy	Class III director and member of the Audit Committee	Appointed	2025-05-29	2025-05-30
J. Scott Wolchko	President, Chief Executive Officer ("CEO"), Chief Financial Officer, Treasurer, principal executive officer, principal financial	Retired	2024-12-31	2025-01-06
Bahram Valamehr	director	Appointed	2025-01-01	2024-11-29
J. Scott Wolchko	President, Chief Executive Officer ("CEO")	Retired	2024-12-31	2024-11-29
J. Scott Wolchko	Chief Financial Officer	Retired	2024-12-31	2024-11-29
Bahram Valamehr	President and CEO	Appointed	2025-01-01	2024-11-29
J. Scott Wolchko	director	Resigned	2024-11-27	2024-11-29
Neelufar Mozaffarian, M.D., Ph.D., FACR	Class II director and member of the NCG Committee and the Science and Technology Committee of the Board	Appointed	2024-07-29	2024-07-31
J. Scott Wolchko	principal financial and accounting officer	Appointed	2024-06-03	2024-06-07
Edward J. Dulac III	Chief Financial Officer	Resigned	2024-06-14	2024-06-07
J. Scott Wolchko	Chief Financial Officer	Appointed	2024-06-03	2024-06-07
Edward J. Dulac III	Chief Financial Officer	Resigned	2024-06-14	2024-05-31
Dr. Yu-Waye (Wayne) Chu, M.D.	Chief Medical Officer	Resigned	2023-07-14	2023-06-08
Mark Plavsic, Ph.D., D.V.M.	Chief Technical Officer	Terminated	2023-03-06	2023-01-05

Key facts CIK 1434316 CUSIP 31189P102 13F (30d) 3 filings 3 filers Visit website Investor relations